Beta Bionics Faces Securities Fraud Lawsuit Over Insulin Pump Claims

NEW YORK, Sept. 13, 2026 /CourierPR/ -- Beta Bionics, Inc., a company listed on the NASDAQ under the ticker symbol BBNX, faces a securities fraud lawsuit from Rosen Law Firm, a global investor rights law firm. The lawsuit targets the company for alleged misrepresentations regarding its automated insulin delivery system, known as the iLet Bionic Pancreas insulin pump.

According to the lawsuit, Beta Bionics made false and misleading statements to the market about the safety and efficacy of the iLet device. The U.S. Food and Drug Administration (FDA) had raised serious concerns about the device, noting that it was malfunctioning and dosing patients with dangerously high levels of insulin, leading to hypoglycemic events. Despite these issues, Beta Bionics allegedly downplayed the severity of the complaints filed with the FDA, claiming they were of no consequence.

The lawsuit claims that the FDA received thousands of complaints, including hundreds of life-threatening events that required significant medical intervention. However, Beta Bionics failed to implement any meaningful corrective actions, according to the lawsuit. When the true nature of the issues became public, the lawsuit alleges that investors suffered significant financial losses.

Rosen Law Firm is seeking to represent investors who purchased Beta Bionics common stock between July 30, 2025, and February 24, 2026. The firm is urging investors who believe they may have a claim to contact the firm to learn more about their legal rights. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026.

The lawsuit highlights the importance of transparency and accountability in the medical device industry. It underscores the potential consequences for companies that fail to address safety concerns and the need for investors to be vigilant in protecting their interests.